The investment bank gave PerkinElmer an Outperform rating with a $114 stock price target and Hologic an In Line rating with a $55 stock price target.
Earlier this month, the company started accepting clinical samples at its CLIA/CAP laboratory in Pittsburgh and an affiliate laboratory in Malaysia.
Researchers at Baylor College of Medicine and Columbia University found that almost all blood samples from pregnant women tested contained several trophoblasts.
Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.
Clinical genomics is just one business area for PHIX, which also intends to sell genomic tools and introduce a variety of agriculture and lifestyle-focused tests.
A preliminary analysis lends some support to covering NIPS for pregnancies beyond high-risk, and some payors have expanded coverage.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.
The Unity test enables screening for several autosomal recessive conditions from fetal DNA gathered from maternal blood.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.